1. A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). Issue 4 (21st March 2019) Authors: Chen, Christine I.; Paul, Harminder; Snitzler, Susi; Kakar, Sumeet; Le, Lisa W.; Wei, Ellen N.; Lau, Anthea; Johnston, James B.; Gibson, Spencer B.; Queau, Michelle; Spaner, David; Croucher, Danielle; Sherry, Barbara; Trudel, Suzanne Journal: Leukemia & lymphoma Issue: Volume 60:Issue 4(2019) Page Start: 980 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*. Issue 1 (2nd January 2019) Authors: Chen, Christine I.; Paul, Harminder; Le, Lisa W.; Wei, Ellen N.; Snitzler, Susi; Wang, Trina; Levina, Olga; Kakar, Sumeet; Lau, Anthea; Queau, Michelle; Johnston, James B.; Smith, Deborah A.; Trudel, Suzanne Journal: Leukemia & lymphoma Issue: Volume 60:Issue 1(2019) Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines. Issue 8 (2nd July 2020) Authors: Chen, Christine I.; Cao, Yanshuo; Trudel, Suzanne; Reece, Donna E.; Kukreti, Vishal; Tiedemann, Rodger; Prica, Anca; Paul, Harminder; Le, Lisa W.; Levina, Olga; Kakar, Sumeet; Lau, Anthea; Chen, Hongzhuan; Chen, Eric Journal: Leukemia & lymphoma Issue: Volume 61:Issue 8(2020) Page Start: 1860 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗